Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...

Baron International Growth Fund increased in the third quarter of 2024, modestly outperforming its benchmark, the MSCI ACWI ...

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Mangoceuticals (NASDAQ:MGRX), which operates the men’s health platform MangoRx, said it strongly refutes any and all claims ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for preventing strokes.

The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...